Login to Your Account

Pharma: Clinic Roundup

Thursday, August 30, 2012
• Eli Lilly and Co., of Indianapolis, said it is stopping ongoing trials testing promaglumetad methionil, also known as mGlu2/3, for the treatment of schizophrenia, after a recently conducted independent futility analysis concluded that the second of two pivotal studies was unlikely to be positive in its primary efficacy endpoint if enrolled to completion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription